Physician profile
Agnes Sides
NPI 1235505413
$2,435.24
in general payments reported to CMS, 2019-2025
24 companies · $999 in 2025
The $999 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $256 · 2023: $570 · 2024: $509 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,078.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $896.21 | 2022-2025 | |
| Glaxosmithkline, LLC. | $273.16 | 2023-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Csl Behring | $182.70 | 2023-2025 | Andembry, Kcentra |
| Astrazeneca Pharmaceuticals LP | $169.04 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2024 | Dupixent |
| Amgen INC. | $111.49 | 2023-2024 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $98.54 | 2023-2024 | Hyqvia, Takhzyro, Cuvitru |
| Lilly USA, LLC | $86.81 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $66.00 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $64.93 | 2024 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $46.05 | 2025 | |
| Incyte Corporation | $39.71 | 2024-2025 | Opzelura |
| Biocryst US Sales Co., LLC | $36.82 | 2025 | Orladeyo |
| Genentech USA, INC. | $33.76 | 2025 | Xolair |
| Pharming Healthcare, INC. | $28.80 | 2023 | Ruconest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $25.34 | 2025 | |
| Nevro Corp. | $23.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.71 | 2024 | Jardiance |
| Novo Nordisk INC | $21.85 | 2024 | Rybelsus, Ozempic |
| Leo Pharma INC. | $19.32 | 2025 | Anzupgo |
| Amarin Pharma, INC. | $17.72 | 2021 | |
| Grifols USA, LLC | $15.47 | 2025 | Xembify |
| Ultragenyx Pharmaceutical INC. | $15.29 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agnes Sides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.